Adenocarcinomas of the small bowel and ampulla of Vater represent rare cancers that have limited data regarding first-line therapy. We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in patients with advanced adenocarcinoma of small bowel or ampullary origin.
INTRODUCTION
Adenocarcinoma of the small bowel and ampulla of Vater are rare cancers. Approximately 2,500 new patient cases of small bowel adenocarcinoma (SBA) and 2,000 new cases of ampullary adenocarcinoma (AAC) are expected to be diagnosed in the United States in 2008.
1,2 Symptoms of SBA are frequently nonspecific, and the majority of patients present with advanced disease. 3 In contrast, patients with AAC often present earlier in their disease course because of symptoms that result from biliary obstruction. For patients with AAC who undergo surgical resection, survival is similar to that observed in patients with resected duodenal adenocarcinoma, rather than in those with resected pancreaticobiliary carcinomas. Large, single-institution series of patients with resected periampullary carcinomas have demonstrated 5-year survival rates of 10% to 15% for those with pancreatic adenocarcinoma, 27% to 30% for those with extrahepatic cholangiocarcinoma, 32% to 68% for those with AAC, and 54% to 59% for those with duodenal adenocarcinoma. [4] [5] [6] [7] However, for patients who relapse or who present with metastatic SBA or ACC, the prognosis is poor, and the reported OS rate at 2 years is 5% to 10%. 8, 9 For advanced SBA and AAC, limited data exist to guide physicians in their choices of chemotherapy, and there is no standard chemotherapeutic regimen for previously untreated patients. The most commonly studied cytotoxic agent for SBA has been fluorouracil (FU). Small, retrospective studies have demonstrated response rates of 0% to 36% with primarily single-agent FU. [10] [11] [12] [13] Only one prospective, phase II study has evaluated chemotherapy in patients with advanced SBA and AAC.
14 That study,
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conducted by the Eastern Cooperative Oncology Group (ECOG), evaluated the combination of FU, doxorubicin, and mitomycin (FAM) in 38 patients with either SBA or AAC. This regimen demonstrated an 18% response rate and a median OS of 8 months. Despite the lack of published data, gemcitabine-based treatment frequently has been used for the treatment of AACs. At M. D. Anderson Cancer Center (Houston, TX), the general approach to periampullary cancers has been to use gemcitabine-based therapy for pancreatic and biliary carcinomas and FU-based therapy for duodenal and ampullary carcinomas.
On the basis of anecdotal activity of a fluoropyrimidine and a platinum doublet in SBA and AAC, and on the basis of proven activity of this combination in other advanced gastrointestinal cancers, we designed this phase II study to evaluated the activity of capecitabine and oxaliplatin (CAPOX) in advanced SBA and AAC. 15, 16 
PATIENTS AND METHODS

Patients
All eligible patients were required to have histologically confirmed SBA or AAC; measurable metastatic or locally unresectable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST); ECOG performance status of 0 to 2; and adequate hematologic (granulocyte count Ն 1,500 cells/ mm 3 , platelet count Ն 100,000 cells/mm 3 , and hemoglobin Ն 10 gm/dL), hepatic (total bilirubin Յ 1.5 gm/dL, albumin Ն 2.5 gm/dL, and transaminases Ͻ 2ϫ the upper limit of normal without liver metastases or Ͻ 5ϫ with liver metastases), and renal function (creatinine Յ 1.5ϫ the upper limit of normal and creatinine clearance Ͼ 30 mL/min). Prior chemotherapy for metastatic disease was not allowed, but prior use of a fluoropyrimidine (including capecitabine) as a radiosensitizer or as adjuvant therapy was permitted. An interval of at least 4 weeks was required from prior surgery, radiation therapy, or adjuvant therapy. Patients with prior platinum chemotherapy, brain metastases, peripheral neuropathy of grade 2 or greater, concurrent therapeutic warfarin use, uncontrolled concurrent serious medical illness, the inability to take oral medications, or gastrointestinal malabsorption were not eligible to participate in the study. The University of Texas M. D. Anderson Cancer Center institutional review board approved this study protocol, and all patients gave written informed consent.
Study Design
This was an open-label, single-arm, single-institution, phase II study conducted at The University of Texas M. D. Anderson Cancer Center. Treatment consisted of intravenous (IV) oxaliplatin 130 mg/m 2 on day 1 and oral capecitabine 750 mg/m 2 twice daily on days 1 through 14 of each treatment cycle. Treatment cycles were repeated every 21 days.
Staging procedures were conducted every 9 weeks. All responses required confirmation by imaging studies at 6 weeks or more after the initial documented response. Patients were removed from the study if they withdrew their consent, if they experienced unacceptable toxicity, if they had a treatment delay of greater than 2 weeks because of toxicity from study treatment, or if the investigator deemed withdrawal was in the patient's best interest.
Dose Reductions
All toxicities were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0, except for neurotoxicity. Initiation of a cycle of CAPOX required grade 1 or lower granulocytopenia, grade 1 or lower thrombocytopenia, and recovery from any treatment-related nonhematologic toxicity (excluding alopecia and neurosensory toxicity) to baseline or to grade 1 or lower.
Capecitabine was interrupted during a cycle for grades 3 or 4 hematologic toxicity (excluding anemia) or for grade 2 or greater nonhematologic toxicity (excluding grade 2 nausea or vomiting). Capecitabine dosage was reduced 25% for grade 2 hand-foot syndrome, 50% for grade 3 hand-foot syndrome, 25% for grade 3 nonhematologic toxicity, 50% for grade 4 nonhematologic toxicity, or 25% for a delay in hematologic recovery of greater than 1 week (excluding anemia). Oxaliplatin dosage was reduced by 25% for grades 3 or 4 hematologic toxicity (excluding anemia), grades 3 or 4 nonhematologic toxicity (excluding hand-foot syndrome), a delay in hematologic recovery of greater than 1 week (excluding anemia), or paresthesias with pain or functional impairment longer than 7 days. Oxaliplatin was discontinued if paresthesias with pain or functional impairment persisted throughout a cycle.
Statistical Analysis
The primary end point was overall radiographic response rate as assessed by the treating investigator. Responses were determined according to RECIST. Secondary end points included toxicity, time to disease progression (TTP), and OS. TTP and OS were defined as the time from first study treatment to date of disease progression or death, respectively. In addition to the standard TTP analysis, a second on-study TTP analysis was conducted; patients who received new anticancer therapy (eg, radiation therapy, surgical resection, or additional chemotherapy) before disease progression were censored at the date of the last tumor assessment before the new anticancer therapy. Both OS and TTP were analyzed with the Kaplan-Meier method. The efficacy analysis was based on the intent-to-treat population.
The Bayesian design of Thall et al 16 was used for an acceptable balance of risk and benefit by continuously monitoring the response rate, the proportion of patients who required hospitalization, and the proportion of patients who experienced grades 3 or 4 peripheral neuropathy. The accrual goal was 30 patients. Toxicity data were analyzed in all patients who received at least one dose of study medication.
RESULTS
Baseline Characteristics
Between November 1, 2004 and July 31, 2007, 31 patients with advanced SBA and AAC were enrolled. One patient who did not meet eligibility criteria and who did not receive any study treatment was excluded from the intent-to-treat population. One additional patient developed an acute flare of Crohn's disease after one cycle of study treatment and was removed from the study without undergoing restaging scans.
The baseline characteristics of the intent-to-treat population are listed in Table 1 . Metastatic disease was present in 83% of patients, and the ECOG performance status was 0 or 1 in 96% of patients. There were 12 patients with AAC, which represented 40% of the study population. Four patients received adjuvant IV FU and had a median time interval between completion of adjuvant therapy and study entry of 20 months (range, 4 to 38 months). One patient received prior IV FU as a radiation sensitizer for treatment of locally advanced disease. This patient subsequently developed metastatic disease and was enrolled on the study 2 months after completion of chemoradiotherapy.
Study Drug Administration
A total of 175 cycles were administered (median, 5 cycles; range, 1 to 14 cycles), and 69% of all cycles were given at full dose. Compliance with capecitabine was excellent, as greater than 95% of all scheduled doses were taken. Fourteen patients required at least one dose reduction. Oxaliplatin dose was reduced in 10 patients, four of whom required a second dose reduction. Most dose reductions were due to fatigue (40%) and peripheral neuropathy (30%). Capecitabine dose was reduced in 12 patients, three of whom required a second dose reduction; fatigue (42%) and diarrhea (25%) were the most common causes for capecitabine dose reduction. The median cycle for the first dose reduction was cycle 4 (range, cycles 2 to 8). Major reasons for A n t i a L a b o r a t o r i e s I n c .
h t t p : / / w w w . a n t i a l a b s . c o m treatment discontinuation were disease progression (33%), toxicity (27%), treatment with radiation or surgery (17%), and chemotherapy break (13%).
Toxicity
All patients who received one dose of study treatment were evaluated for toxicity (N ϭ 30). The most common treatment-related, grades 2 to 4 adverse events are listed in Table 2 . The most common grades 3 to 4 adverse events were fatigue (30%), peripheral neuropathy (10%), diarrhea (10%), vomiting (10%), and neutropenia (10%). Only one grade 4 toxicity occurred; this patient had asymptomatic pulmonary emboli on initial radiographic restaging; after an institutional review board exemption was obtained, this patient remained in the study. There were no treatment-related deaths.
Efficacy
The primary end point for this study was objective response rate (Table 3) . According to intent-to-treat analysis, 15 patients responded to treatment, which provided an overall response rate of 50% (95% CI, 31% to 69%). Patients with SBA (n ϭ 18) had a response rate of 61% (95% CI, 36% to 83%), and patients with AAC (n ϭ 12) had a response rate of 33% (95% CI, 10% to 65%). Three patients, all with metastatic disease, had a complete response to CAPOX (two with AAC and one with SBA). In two of these patients, metastatic disease was biopsy proven: liver metastasis in one patient, and supraclavicular lymph node metastasis in the second. The third patient, who underwent resection of localized ACC, had postoperative imaging that demonstrated interval appearance of three new liver lesions, all of which were documented as enlarged before study entry. All three patients were currently alive without evidence of disease at 30, 25, and 24 months from the completion of CAPOX chemotherapy, respectively. Two were treated with CAPOX alone, and the third patient received CAPOX followed by consolidative radiation therapy to the duodenal primary and supraclavicular lymph node metastasis. An additional 11 patients (37%; 95% CI, 20% to 56%) had stable disease. Figure 1 depicts a waterfall plot of best tumor response per RECIST criteria.
At a median follow-up of 14 months, the median TTP was 11.3 months (95% CI, 4.7 to Ͼ 35 months). The median TTP censored for subsequent anticancer treatment was 9.8 months (95% CI, 4.4 to Ͼ 35 months; Fig 2A) . Median OS was 20.4 months (95% CI, 14.4 to Ͼ 35 months; Fig 2B) . The OS rate was 75% (95% CI, 39% to 92%) at 1 year and was 26% (95% CI, 0% to 74%) at 3 years.
Three of the five patients with locally advanced, unresectable disease subsequently underwent surgical resection, and they were currently alive without evidence of disease at 10, 10, and 14 months after surgery, respectively. An exploratory analysis was conducted on patients with metastatic disease only (Table 3) . In this subgroup, the median TTP was 9.4 months (95% CI, 4.4 to 17.7 months); TTP, when censored for subsequent anticancer therapy, was 6.6 months (95% CI, 4.4 to 17.7 months). The median OS was 15.5 months (95% CI, 12.8 to 31.2 months), and the OS rate was 70% (95% CI, 33% to 89%) at 1 year and was 19% (95% CI, 0% to 66%) at 3 years. A n t i a L a b o r a t o r i e s I n c .
DISCUSSION
This prospective, phase II study provides important insights for the treatment of patients with SBA and AAC. CAPOX proved highly active, with an overall response rate of 50% and a median OS of 20.4 months. Treatment was well-tolerated, and fatigue, which represented the most common grades 3 or 4 toxicity, occurred in 30% of patients. Prospective studies have not evaluated the benefit of chemotherapy compared with best supportive care in the treatment of advanced AAC and SBA. However, single-institution retrospective studies have suggested that palliative chemotherapy confers a survival benefit to patients with SBA. 10, 17, 18 In the largest report, which evaluated 113 patients with advanced SBA, the multivariate predictors of improved OS were treatment with palliative chemotherapy, nonmetastatic disease, good performance status, and well-to moderately differentiated histologic grade.
18
The outcome of the current study compares favorably with previous reports that investigated the role of chemotherapy, primarily, in adenocarcinoma of the small bowel (Table 4 ). In the only prior prospective, phase II study, which was conducted by the ECOG, the combination of FAM demonstrated a response rate of 18% and a median OS of 8 months.
14 Of note, the ECOG study was multiinstitutional, and it enrolled a population with a poorer prognosis, as 30% of the patients had a performance status of 2. Our results also compare well with two recent retrospective studies that evaluated treatment with combinations of FU and a platinum compound, in which response rates were 20% to 41%, and median OS rates were 14 to 15 months. 19, 21 The occurrence of durable complete responses in three patients (10%) in this study was unexpected. Two of these patients had biopsyproven metastatic disease, and the third patient had liver metastases that developed shortly after pancreaticoduodenectomy for ACC. In comparison, the rate of complete remission to multiagent chemotherapy in phase III trials of colorectal cancer is approximately 3% to Change From Baseline (%) 4%. 22, 23 In the prior ECOG study of FAM for SBA and AAC, two of the seven observed responses were complete responses. 15 Though not statistically different, the response rate for AAC in this study appeared lower than the rate for SBA (33% v 61%, respectively). This difference may reflect the heterogeneous epithelium of origin for ampullary tumors, as the ampulla of Vater contains epithelium of duodenal, pancreatic, and biliary origin. Expression of the caudal-type homeodomain transcription factors 1 (CDX1) and 2 (CDX2) have been shown recently to separate AAC into two distinct groups that have significantly different survival rates. 24 It has been postulated that CDX2 expression may help to distinguish an intestinal-like carcinoma with good prognosis from a pancreaticobiliary carcinoma with poor prognosis.
2 It is possible that a subset of the patients with ampullary carcinomas had pancreaticobiliary profiles that might be less responsive to CAPOX; this might explain the lower response rate for these patients, though the sample size is small. In the current era of molecular diagnostics, additional elucidation of the molecular heterogeneity of ampullary cancers may aid in the development of individualized therapies for these patients.
The capecitabine dose used in this study was 750 mg/m 2 twice daily, which is a lower dose than that used in recent, phase III, colorectal cancer trials that demonstrated the noninferiority between CAPOX and the combination of continuous infusion FU, leucovorin, and oxaliplatin. 25, 26 This dose was selected on the basis of an earlier phase II study that demonstrated increased toxicity with the use of a higher capecitabine dose in combination with oxaliplatin. 27 We believe this more modest dose helped to minimize the toxicity of the CAPOX regimen, and we suggest that this dose may help explain the impressive efficacy of CAPOX observed in our study. This is supported by the results from the TREE-1 and TREE-2 studies in advanced colon cancer, which demonstrated reduced toxicity and improved efficacy once the protocol was amended to lower the starting dose of capecitabine. 28 In addition, capecitabine tolerance has been linked to geographic location: patients in the United States have demonstrated increase toxicity to equivalent doses of capecitabine than patients in the rest of the world. 29 There are some limitations to our study. First, this study was conducted at a single institution, and a selected group of patients were enrolled. Because of the rarity of the diseases studied, the majority of patients were referred with good performance status, which thereby limited the applicability to patients with worse performance status. Second, the small sample size hampers comparisons between various subgroups within the study (eg, ACC v SBA; locally advanced disease v metastatic disease). Nevertheless, to separate the heterogeneity in progression and survival outcomes between the locally advanced and metastatic patients, an exploratory analysis of the metastatic subgroup was performed.
Importantly, this trial demonstrates the feasibility of the completion of phase II studies in rare tumor types, and these exciting results should provoke more robust research efforts in these orphan tumors. Specifically, the encouraging efficacy of CAPOX in advanced disease suggests that it should be investigated as a component of adjuvant therapy for patients who undergo surgical resection of localized ACC or SBA. In addition, given the overall tolerability of the regimen, it is logical to investigate the role of targeted therapies in combination with CAPOX. For example, in patients with advanced colorectal carcinoma, the addition of bevacizumab to either CAPOX or infusional FU, leucovorin, and oxaliplatin was found recently to prolong PFS compared with cytotoxic chemotherapy alone, and clinical trials that investigate CAPOX in combination with agents targeting angiogenesis would be reasonable for patients with SBA and ACC. 25, 30 In addition, activation of mutations in the KRAS oncogene occur at a similar frequency in both small bowel adenocarcinoma and colon adenocarcinoma, which implicates a potential role for epidermal growth factor receptor inhibition in a subset of patients with SBA and, possibly, AAC. 31, 32 In conclusion, in patients with good performance status, CAPOX is well tolerated and highly effective. The response rate, TTP, and OS are extremely favorable compared with those reported in the literature for other regimens, and they suggest that this combination should represent a new standard for the treatment of advanced SBA and AAC.
